Clinical factors predicting nemolizumab response in atopic dermatitis
Clinical predictors of response to nemolizumab, an anti-IL-31 receptor A antibody, were evaluated in patients with atopic dermatitis (AD). In a retrospective study of 14 Japanese patients, longer disease duration was significantly associated with poor response to treatment. While serum IgE levels an...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2025-05-01
|
| Серія: | Journal of Allergy and Clinical Immunology: Global |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S277282932500058X |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|